The U.S. Treasury doubled the minimum size of long-end buyback operations from $2 billion to $4 billion per operation. Stanley Druckenmiller called the move price management rather than liquidity management. This report tests both arguments against the mechanics of buybacks, empirical liquidity evidence, a $2.1 trillion fiscal deficit, $40 trillion of federal debt, and the latest yield response, then maps the implications for AI capex, semiconductors, and Korean equities.
NVIDIA reported fiscal Q2 2027 revenue of $96.2 billion and Data Center revenue of $89.0 billion. The more consequential disclosures were an approximately 70% fiscal 2028 growth outlook, faster ACIE growth, memory-driven margin pressure, $279 billion of supply commitments, and $108.5 billion of maximum guarantee exposure.
The Bank of Korea raised its policy rate from 2.75% to 3.00% in August 2026. A sharp growth upgrade, sticky core inflation, rising Seoul home prices, and accelerating household credit all pushed in the same direction. This report examines the decision, the historical cycle, the six-month conditional rate path, and the scenarios for Korea's economy and equity market.
This piece lines up projected 2027 return on equity and price-to-earnings multiples for fourteen Korean stocks as of the August 21, 2026 close, then compares each stock's conservative value range with its current price. The short answer: this is a list of good companies, not a list of cheap stocks. Seven of the fourteen have a value-range midpoint above the current price, and five have a current price above even the top of the range. The character of that reference date matters too. The KOSPI rose 0.88% that day, yet 683 of 876 issues fell, and the KOSDAQ dropped 4.63%, triggering a sell-side sidecar. Thirteen of the fourteen prices in the table come from a day the market fell. Earnings were mostly solid: Samsung E&A grew operating profit 51% and filled 3 trillion won in new orders, while Daeduck Electronics grew revenue 63.1% and multiplied operating profit thirty-sevenfold. Even so, the names with the most room and the names with the best earnings do not rank in the same order. This piece works through that mismatch with the numbers, and also covers the table's internal consistency check and the limits of the method.
Sorting biotech into oncology, obesity, and rare disease does not let you compare investment risk. You need to overlay four axes: disease, treatment modality, value chain, and economics, and the axis that actually divides risk is economics, meaning whether the payoff is a one-time milestone tied to a single trial or recurring revenue per patient. This piece rearranges fourteen sub-themes around where the money actually gets made, and dissects personalized oncology, where Moderna's stock jumped 177% in a single day on the August 19 Phase 3 success. In this theme, where therapeutics, diagnostics, recurrence monitoring, and data all fold into one pipeline, the economics differ at every stage. Natera's second-quarter revenue grew 37.7% and oncology testing grew 57%, while Tempus posted its first profitable quarter, which included a $98.5 million unrealized gain. But the Phase 3 trial only randomized 1,137 patients, manufacturing success rates and hazard ratios have not yet been disclosed, and the leading diagnostics names trade at 16x to 17x revenue. The conclusion is a barbell structure that separates companies that only earn if their drug works from companies that earn no matter which drug works, and all three stocks discussed here have just gone through sharp rallies, so entry-price discipline is essential.
The US biotech ETF (XBI) is up +88.8% in a year, and money is rotating from semiconductors into biotech. Three engines drive it: an M&A supercycle ($123B+ in H1), rate-cut hopes, and a reopened IPO window. Then two events in mid-August redrew the theme map: the first-ever Phase 3 win for an mRNA cancer therapy, and lab-validated protein design by an AI (Claude). This post explains all 8 themes in beginner language: next-gen obesity, China licensing, M&A, radioligand therapy, CNS, autoimmune cell therapy, AI drug discovery, and the mRNA renaissance. It then maps the Korean names actually connected by contracts (Alteogen, HanAll, LigaChem, ABL Bio, ST Pharm, OliX and more) on a 'contract substance × price momentum' grid. Includes 8 visuals. Data as of the 2026-08-19 close.
While the KOSPI rose 11.49% from August 10 to 14, retail investors net sold around 7 trillion won and foreign investors net bought in the mid-6 trillion won range. But when the full period since the July 30 low is split into phases, foreign buying was not continuous. It came in two bursts. Foreigners absorbed capitulation supply in a single day on July 31, sold back into the stall period in early August, and bought again from August 12 once the inflation-driven rally began. The methodological lesson of this breakdown is that cutting the window from August 1 instead produces the opposite conclusion: retail net buying and foreign net selling. And the rebound's buying returned to the same spot as the crash's selling. Half of net buying was concentrated in Samsung Electronics and SK Hynix, where foreign and institutional investors absorbed the supply that retail sold. The remaining caveat is futures and program trading. With cash equities bought but futures shorts not fully unwound, the structure is mixed, and confirming a full return to trend depends on four follow-up checks.
This piece verifies the claim that AI's bottleneck has moved from the GPU to HBM. Morgan Stanley's report frames the bottleneck as moving along the supply chain, from chips to power, memory, networking, and cooling, but the figure of roughly 50 billion Gb in 2027 HBM demand that circulates alongside it does not come from that document. It comes from Korean brokerages and research aggregation, and three separate estimates converge on the same range. The core of the claim holds up: compute grows three to four times per generation while bandwidth grows more slowly, agent inference occupies memory through the KV cache, and HBM consumes three times the wafers per bit while yield at 16 layers falls below half, so 2027 supply is effectively locked in by physics. But the same arithmetic is moving buyers too. NVIDIA cut module capacity in half once memory cost reached 29% of system cost, reports say the next flagship's HBM specification will be set below the prior generation, and prefill-only chips skip HBM entirely. It lays out the bottleneck's reality alongside the workarounds it is provoking, and where that leaves the profits of Korean memory makers in between.
Two things became official on a single day, August 10. The SEC excluded data center securitization bonds from asset-backed securities regulation, and NVIDIA announced a $500bn third-party capital platform with six partners ranging from Apollo to KKR. The shift of AI capital expenditure financing from corporate balance sheets to capital markets was confirmed on both the regulatory and structural fronts in one day. The same week, CoreWeave and Nebius demonstrated demand through earnings, SanDisk disclosed that multi-year contracts now cover two-thirds of its NAND shipments, and SK Hynix Chairman Chey Tae-won pulled out, on camera, a supply request that Jensen Huang had handwritten on a wafer. US inflation data broke the odds of a rate hike, and the KOSPI rose for four straight days. This piece reviews a week in which all three observation items left by the previous post were filled in, and lays out what remains unresolved.
Last week the KOSPI rose 3.76%, fell 4.58%, and fell another 0.60% over three days. The trigger for the plunge on the 6th was not macro but guidance from AMD and SanDisk, and oil prices and interest rates were actually favorable that day. This piece scores five candidate axes for a rebound (macro, NVIDIA earnings, shareholder returns, export data, and product qualification) for impact and timing. The conclusion is that a single trigger is not enough. NVIDIA beat estimates for four straight quarters without its stock rising, and Samsung Electronics closed lower on the day it reported its highest-ever earnings. Then on August 7, SK Hynix announced a $38bn capacity expansion, making shareholder returns and supply discipline two sides of the same decision. The earliest leading signal is not a trigger but the first instance of two consecutive up days on good news.